We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
EAMA
101
EFG Asset Management (Americas)
Florida
$2.09M +$229K +1,508 +11%
TI
102
Trexquant Investment
Connecticut
$2M +$2.17M +14,313 New
SSA
103
Schonfeld Strategic Advisors
New York
$2M +$653K +4,300 +43%
Russell Investments Group
104
Russell Investments Group
United Kingdom
$2M -$12.9M -85,234 -86%
ProShare Advisors
105
ProShare Advisors
Maryland
$1.97M -$405K -2,666 -16%
Squarepoint
106
Squarepoint
New York
$1.93M -$1.48M -9,759 -41%
CIA
107
Capital Impact Advisors
Massachusetts
$1.91M
State Board of Administration of Florida Retirement System
108
State Board of Administration of Florida Retirement System
Florida
$1.9M +$148K +976 +8%
Dimensional Fund Advisors
109
Dimensional Fund Advisors
Texas
$1.85M -$4.69M -30,872 -70%
CIP
110
Chartwell Investment Partners
Pennsylvania
$1.76M +$59K +389 +3%
CEP
111
Chicago Equity Partners
Illinois
$1.72M -$14.4K -95 -0.8%
MIM
112
MetLife Investment Management
New Jersey
$1.7M
Creative Planning
113
Creative Planning
Kansas
$1.67M -$408K -2,690 -18%
Bank of Montreal
114
Bank of Montreal
Ontario, Canada
$1.65M +$63.1K +416 +4%
AI
115
Axiom Investors
Connecticut
$1.54M -$763K -5,028 -31%
DekaBank Deutsche Girozentrale
116
DekaBank Deutsche Girozentrale
Germany
$1.53M -$373K -2,460 -18%
SO
117
STRS Ohio
Ohio
$1.53M +$15.2K +100 +0.9%
Legal & General Group
118
Legal & General Group
United Kingdom
$1.51M +$96.2K +634 +6%
Principal Financial Group
119
Principal Financial Group
Iowa
$1.42M -$794K -5,233 -34%
AR
120
Advisory Research
Illinois
$1.41M +$36.9K +243 +2%
RPAM
121
Rhenman & Partners Asset Management
Sweden
$1.4M -$6.07M -40,000 -80%
SGH
122
Sivik Global Healthcare
Connecticut
$1.4M -$759K -5,000 -33%
EP
123
Eversept Partners
New York
$1.4M +$1.52M +10,000 New
N
124
Nuveen
North Carolina
$1.24M +$96.7K +637 +8%
CCI
125
Columbus Circle Investors
$1.23M -$1.37M -9,005 -51%

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.